{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:51:59Z","timestamp":1792522319308,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.bbmt.2019.01.033","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T06:23:21Z","timestamp":1549002201000},"page":"1331-1339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab"],"prefix":"10.1016","volume":"25","author":[{"given":"Jason P.","family":"Cooper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafic J.","family":"Farah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted A.","family":"Gooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9343-4099","authenticated-orcid":false,"given":"Rainer","family":"Storb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9620-7839","authenticated-orcid":false,"given":"Bart L.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2019.01.033_bib0001","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199511093331904","article-title":"Natural history of paroxysmal nocturnal hemoglobinuria","volume":"333","author":"Hillmen","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0002","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/asheducation-2016.1.208","article-title":"Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria","volume":"2016","author":"Parker","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0003","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1172\/JCI117234","article-title":"Paroxysmal nocturnal hemoglobinuria and the glycosylphosphatidylinositol anchor","volume":"93","author":"Yeh","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0004","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1182\/blood.V108.11.985.985","article-title":"The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire","volume":"108","author":"Hill","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0005","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1182\/blood.V93.10.3451.410k27_3451_3456","article-title":"Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia","volume":"93","author":"Hugel","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0006","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.thromres.2003.09.018","article-title":"Thrombosis in patients with paroxysmal nocturnal hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor","volume":"111","author":"Liebman","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0007","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1084\/jem.163.1.221","article-title":"Decay-accelerating factor is present on cultured human umbilical vein endothelial cells","volume":"163","author":"Asch","year":"1986","journal-title":"J Exp Med"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0008","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.293.13.1653","article-title":"The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease","volume":"293","author":"Rother","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0009","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1182\/blood.V87.12.5332.bloodjournal87125332","article-title":"The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria","volume":"87","author":"Hall","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0010","doi-asserted-by":"crossref","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","article-title":"Paroxysmal nocturnal haemoglobinuria","volume":"3","author":"Hill","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0011","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(95)12360-1","article-title":"Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology","volume":"348","author":"Soci\u00e9","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0012","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0013","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0014","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0015","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","article-title":"Paroxysmal nocturnal hemoglobinuria","volume":"124","author":"Brodsky","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0016","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0017","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2141.1973.tb01701.x","article-title":"Paroxysmal nocturnal haemoglobinuria and refractory marrow failure treated by marrow transplantation","volume":"24","author":"Storb","year":"1973","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0018","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3324\/haematol.2010.023176","article-title":"Stem cell transplantation for paroxysmal nocturnal hemoglobinuria","volume":"95","author":"Brodsky","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0019","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1182\/blood-2009-03-195966","article-title":"How I treat paroxysmal nocturnal hemoglobinuria","volume":"113","author":"Brodsky","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0020","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1083-8791(03)00264-7","article-title":"Hematopoietic cell transplantation from related and unrelated donors after minimal conditioning as a curative treatment modality for severe paroxysmal nocturnal hemoglobinuria","volume":"9","author":"Hegenbart","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0021","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.3324\/haematol.2012.062828","article-title":"Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria","volume":"97","author":"Peffault de Latour","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0022","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1034\/j.1600-0609.2003.00097.x","article-title":"Allogeneic hematopoietic cell transplantation for paroxysmal nocturnal hemoglobinuria","volume":"71","author":"Lee","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0023","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3324\/haematol.2009.017269","article-title":"Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"95","author":"Santarone","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0024","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1179\/1607845414Y.0000000195","article-title":"Reduced-intensity stem cell allografting for PNH patients in the eculizumab era: the Mexican experience","volume":"20","author":"Schcolnik-Cabrera","year":"2015","journal-title":"Hematology"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0025","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ajh.2830390409","article-title":"Marrow transplantation for paroxysmal nocturnal hemoglobinuria","volume":"39","author":"Kawahara","year":"1992","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0026","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/sj.bmt.1703259","article-title":"Conditioning with high-dose cyclophosphamide may not be sufficient to provide a long-term remission of paroxysmal nocturnal hemoglobinuria following syngeneic peripheral blood stem cell transplantation","volume":"28","author":"Cho","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0027","series-title":"Thomas' Hematopoietic Cell Transplantation","first-page":"537","article-title":"Hematopoietic cell transplantation for paroxysmal nocturnal hemoglobinuria","author":"Nakamura","year":"2016"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0028","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0029","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3109\/10428194.2012.762978","article-title":"Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future","volume":"54","author":"Ram","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0030","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1182\/blood-2003-02-0482","article-title":"HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies","volume":"102","author":"Maris","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0031","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/JCO.2012.45.0247","article-title":"Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation","volume":"31","author":"Storb","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0032","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1182\/blood-2008-01-133918","article-title":"Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories","volume":"112","author":"de Latour","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0033","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.bbmt.2014.05.012","article-title":"Long-term outcome of fludarabine-based reduced-intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuria","volume":"20","author":"Pantin","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0034","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3109\/10428194.2015.1068309","article-title":"Haploidentical hematopoietic stem cell transplant in paroxysmal nocturnal hemoglobinuria","volume":"57","author":"Tian","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0035","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0036","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1177\/0272989X14539731","article-title":"Opportunity cost of funding drugs for rare diseases: the cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"34","author":"Coyle","year":"2014","journal-title":"Med Decis Making"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0037","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/bloodadvances.2018020644","article-title":"Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b\/2 studies","volume":"2","author":"R\u00f6th","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0038","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/bmt.2011.88","article-title":"Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike","volume":"47","author":"Danylesko","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0039","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1172\/JCI61019","article-title":"Antigen-presenting cell-derived complement modulates graft-versus-host disease","volume":"122","author":"Kwan","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0040","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood.V126.23.3076.3076","article-title":"Targeting host complement C3a\/C5a receptors to control of acute graft-versus-host disease in mice","volume":"126","author":"Nguyen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.01.033_bib0041","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4172\/2155-9864.1000274","article-title":"The role of complement system in graft versus host disease","volume":"6","author":"Cherry","year":"2015","journal-title":"J Blood Disord Transfus"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119300916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119300916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:08:13Z","timestamp":1761059293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879119300916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1083879119300916"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.01.033","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.01.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}